This is a routine annual proxy filing with no material developments. Monitor the company's next 10-Q or 10-K filing for financial performance updates and any changes in guidance.
AXSM drugs
AXSM drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $187.40entry
- T+1 · 7mo ago −1.28%α −0.80% · $185.00
- T+5 · 7mo ago +19.37%α +18.97% · $223.70
- T+20 · 6mo ago +24.97%α +20.02% · $234.20
- T+60 · 4mo ago +27.87%α +23.09% · $239.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome Therapeutics is holding its 2026 annual meeting for shareholders to vote on director elections, auditor ratification, and executive compensation. This is a routine annual governance filing with no material financial or strategic changes disclosed.
Key Financial Metrics
Key Facts
- Annual shareholder meeting scheduled for June 5, 2026
- Voting on election of two directors: Mark Saad and Susan Mahony
- Ratification of Deloitte & Touche LLP as independent auditor
- Advisory vote on executive compensation
- No material financial data, strategic changes, or unexpected events disclosed
Financial Impact
No financial impact from this filing
Risk Factors
- None disclosed in this filing
- Routine governance risk associated with any shareholder vote
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001193125-26-177613 |
| Document: 0001193125-26-177613-index-headers.html | 0001193125-26-177613 |
| Document: 0001193125-26-177613-index.html | 0001193125-26-177613 |
| Document: 0001193125-26-177613.txt | 0001193125-26-177613 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers